Metazero

Metoprolol succinate, the active ingredient in Metazero, is a beta blocker presented as a tablet for oral use. It treats hypertension, angina pectoris, chronic heart failure and is used for post‑myocardial infarction prophylaxis in adults.

GNH USA supplies Metazero as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metazero (metoprolol succinate) is a beta‑adrenergic blocker used in cardiovascular disease management.

- Hypertension: lowers systemic blood pressure and reduces vascular resistance. - Angina pectoris: decreases frequency and severity of chest pain episodes. - Chronic heart failure: improves functional capacity and reduces hospitalisation risk. - Post‑myocardial infarction prophylaxis: lowers the chance of recurrent cardiac events.

Metazero may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Fatigue or tiredness - Dizziness or light‑headedness - Bradycardia (slow heart rate) - Cold extremities - Gastrointestinal upset (nausea, abdominal discomfort) - Mood changes such as mild depression

Serious or Rare Side Effects: - Severe bradycardia or heart block - Marked hypotension - Bronchospasm, especially in patients with asthma or COPD - Allergic reactions (rash, angioedema, anaphylaxis) - Worsening heart failure symptoms - Cardiogenic shock in extreme cases

Before initiating Metazero, clinicians should assess individual risk factors and monitor patients closely.

- Blood pressure monitoring: ensure adequate control before dose escalation. - Renal impairment: adjust dose in patients with reduced kidney function. - Abrupt discontinuation: taper gradually to avoid rebound tachycardia. - Respiratory disease: use with caution in asthma or COPD. - Diabetes: monitor glucose as beta‑blockade may mask hypoglycaemia. - Store at room temperature: keep in the original container, protect from moisture and light.

Metazero can interact with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Combined use with other AV‑node blockers (e.g., verapamil, diltiazem) may cause profound bradycardia. - Concomitant clonidine therapy: abrupt withdrawal can precipitate hypertensive crisis. - Potent CYP2D6 inhibitors (e.g., quinidine, fluoxetine) increase metoprolol plasma levels. - MAO inhibitors: risk of severe hypertension. - Insulin or sulfonylureas: beta‑blockade may mask hypoglycaemic symptoms.

Moderate Interactions (Monitor Closely): - NSAIDs: may attenuate antihypertensive effect. - Diuretics: additive hypotensive effect, monitor electrolytes. - Calcium‑channel blockers (e.g., amlodipine): may enhance heart‑rate reduction. - Antidiabetic agents: may require dose adjustment. - SSRIs or other antidepressants: potential for increased bradycardia.